Oral News and Research

RSS

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced that results from a clinical study evaluating the safety and efficacy of Caldolor Injection in treating fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Next stop for health law appeal includes two GOP-appointed judges

The next appeals court to hear challenges to the law will be the 6th Circuit Court in Cincinnati on June 1. The judges have a much different ideological make-up than the Richmond trio: While Circuit Judge Boyce Martin, Jr. was appointed by Jimmy Carter, Circuit Judge Jeffrey Sutton is a George W. Bush appointee and District Judge James Graham was appointed by Ronald Reagan.

13 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Cancer studies from Mercer University headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC).

13 May 2011

Longer looks: Conservatives vs. liberals on Medicare - who's winning?

What you really need to know is that Tuesday was a great day in court for supporters of the Care Act and a very tough one for its opponents. That dynamic could easily change within the next six weeks or so when the 11th Circuit, the 6th Circuit, and the 3rd Circuit also hold their oral arguments on Care Act appeals. Either way, we are one step closer to the end of all of this, and you can bet that the justices were paying attention up the road a bit from Richmond.

13 May 2011

Florida plan to revamp Medicaid raises questions; Texas hospitals complain about Medicaid rate cuts

To visit the low-rise medical offices dotting the sun-bleached highways of Broward County is to meet doctors and patients who complain of being guinea pigs in a social experiment gone wrong.

12 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.

12 May 2011

Kool Smiles inaugurates new San Angelo dental office

Kool Smiles, a leading dental health provider for children and adults, now has opened its doors to additional families in Texas with a new office location in San Angelo. Kool Smiles of San Angelo officially opened on February 7 as the organization continues to expand access to quality dental care for families in underserved communities across the nation.

12 May 2011

Oral health tips for fighting gingivitis

Those who faithfully brush their teeth each morning and night might feel as though they're doing enough to achieve a healthy smile. However, even people with good oral care habits may hear from their dentist or hygienist that they have signs of gingivitis, an early form of gum disease.

12 May 2011

Appeals Court judges appear skeptical of health law arguments, pepper lawyers with frequent questions

The first federal appeals court hearing related to the health overhaul offered a preview of how the Obama administration will likely approach the case before the Supreme Court, which is expected to be its final destination.

12 May 2011

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

12 May 2011

Next stop for health law appeal includes two GOP-appointed judges

As news outlets were chewing over Tuesday's hearing on the health law, the next appeal panel, with two Republican-nominated judges, was announced.

12 May 2011

Oral News and Research

Eli Lilly responds to Amylin's exenatide lawsuit

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

China's SFDA approves TPI anti-diabetic drug Gliclazide

Next stop for health law appeal includes two GOP-appointed judges

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Longer looks: Conservatives vs. liberals on Medicare - who's winning?

Florida plan to revamp Medicaid raises questions; Texas hospitals complain about Medicaid rate cuts

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Kool Smiles inaugurates new San Angelo dental office

Oral health tips for fighting gingivitis

Appeals Court judges appear skeptical of health law arguments, pepper lawyers with frequent questions

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Next stop for health law appeal includes two GOP-appointed judges

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News